EUCTR2007-004736-23-Outside-EU/EEA进行中（未招募）不适用
A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Completion of a prior elvitegravir (GS-9137)/r treatment study without treatment-limiting toxicity.
- •Males and females (of childbearing potential i.e., not surgically sterile or at least two years post-menopausal) must agree to utilize effective contraception methods while on study treatment and for 30 days following the last dose of study drug.
- •The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 379
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 372
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •Females who are pregnant or breastfeeding.
- •Participation in any other clinical trial without prior approval from the sponsor is prohibited while participating in this trial.
- •Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements.
- •Subjects receiving ongoing therapy with any of the medications listed in the excluded concomitant medication list
研究者
相似试验
尚未招募
不适用
A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced / Metastatic Solid Tumorsadvanced or metastatic solid tumorssolid neoplasm10027656NL-OMON53771Merck Sharp & Dohme (MSD)30
进行中（未招募）
1 期
Study of the safety, tolerability, processing by the body, and ability to provoke immune system response of ocular injections of RO7446603 alone and in combination with aflibercept or faricimab in participants with diabetic macular edemaDiabetic macular edema (DME)Eye DiseasesISRCTN14152148Genentech, Inc.75
进行中（未招募）
不适用
A global study to see how safe and effective a Once-weekly tablet containing Aripiprazole is in Children and Adolecents with Tourette's DisorderTourette’s DisorderMedDRA version: 16.0Level: PTClassification code 10044126Term: Tourette's disorderSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000469-11-BGOtsuka Pharmaceutical Development & Commercialization, Inc.156
进行中（未招募）
1 期
A clinical trial to test the safety of aripiprazole in children and adolescents with Tourette’s DisorderTics associated with Tourette’s Disorder in children and adolescentsMedDRA version: 14.1Level: PTClassification code 10044126Term: Tourette's disorderSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-003489-42-NLOtsuka Pharmaceutical Development & Commercialization, Inc.96
进行中（未招募）
1 期
A clinical trial to test the safety of aripiprazole in children and adolescents with Tourette’s DisorderEUCTR2012-003489-42-DEOtsuka Pharmaceutical Development & Commercialization, Inc.96